Maine LD107 would require health insurance coverage for biomarker testing.
Maine LD107 would require health insurance coverage for biomarker testing, including coverage in the MaineCare program. Biomarker testing involves analyzing a patient's tissue, blood, or other biological specimen for the presence of a biomarker. The bill mandates coverage for biomarker testing when supported by medical and scientific evidence, such as FDA-approved tests or FDA drug labels. It also requires prompt approval or denial of prior authorization requests for biomarker testing.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.